Skip to main content

Table 2 Patient characteristics

From: The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting

Variable

Non-BRCA1ness

BRCA1ness

p value

(N = 61)

(N = 55)

Treatment

 Control

27 (44.3)

17 (30.9)

0.198a

 Veliparib/carboplatin

34 (55.7)

38 (69.1

Hormone receptor status

 HR+

48 (78.7)

8 (14.5)

<0.05a

 TN

13 (21.3)

47 (85.5)

Tumor size (cm)

 0–1

0 (0)

0 (0)

0.496a

 >1–2

0 (0)

1 (1.8)

 >2–5

40 (65.6)

31 (56.4)

 >5

19 (31.4)

22 (40.0)

  1. Data presented as number (%)
  2. HR hormone receptor status, TN triple-negative
  3. aPearson’s chi-squared test